AR085748A1 - Piridinonas biciclicas - Google Patents

Piridinonas biciclicas

Info

Publication number
AR085748A1
AR085748A1 ARP120101073A ARP120101073A AR085748A1 AR 085748 A1 AR085748 A1 AR 085748A1 AR P120101073 A ARP120101073 A AR P120101073A AR P120101073 A ARP120101073 A AR P120101073A AR 085748 A1 AR085748 A1 AR 085748A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
cyano
optionally
fluorine
Prior art date
Application number
ARP120101073A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR085748A1 publication Critical patent/AR085748A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP120101073A 2011-03-31 2012-03-29 Piridinonas biciclicas AR085748A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161470076P 2011-03-31 2011-03-31
US201261599022P 2012-02-15 2012-02-15

Publications (1)

Publication Number Publication Date
AR085748A1 true AR085748A1 (es) 2013-10-23

Family

ID=45937491

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101073A AR085748A1 (es) 2011-03-31 2012-03-29 Piridinonas biciclicas

Country Status (9)

Country Link
US (2) US8697673B2 (enExample)
EP (1) EP2691393B1 (enExample)
JP (1) JP5767393B2 (enExample)
AR (1) AR085748A1 (enExample)
CA (1) CA2830027C (enExample)
ES (1) ES2602794T3 (enExample)
TW (1) TW201300384A (enExample)
UY (1) UY33978A (enExample)
WO (1) WO2012131539A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103787839A (zh) * 2014-01-21 2014-05-14 苏州昊帆生物科技有限公司 合成2, 3, 4, 5, 6-五氟苯酚的方法

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1008473A2 (pt) 2009-02-06 2019-04-02 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. compostos heterocíclicos bicíclicos substituídos como moduladores de gama secretase
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
MX2011011753A (es) 2009-05-07 2011-11-29 Janssen Pharmaceuticals Inc Nuevos derivados sustitutos de indazol y aza-indazol como moduladores de la gamma secretasa.
AP2011006034A0 (en) 2009-07-15 2011-12-31 Janssen Pharmaceuticals Inc Substituted triazole and imidazole derivatives as gamma secretase modulators.
MX2012008260A (es) 2010-01-15 2012-08-17 Janssen Pharmaceuticals Inc Novedosos derivados de triazol sustituidos como moduladores de la gamma secretasa.
CA2827969A1 (en) 2011-03-24 2012-09-27 Janssen Pharmaceuticals, Inc. Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
TWI567079B (zh) 2011-07-15 2017-01-21 健生醫藥公司 作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物
TW201345527A (zh) 2012-02-03 2013-11-16 Teva Pharma 拉喹莫德於治療對第一線抗－ＴＮＦα療法無效之克隆氏症患者之用途
AU2013261023B2 (en) * 2012-05-16 2016-11-24 Cellzome Limited Substituted 3, 4 - dihydro - 2H - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) Alzheimer's disease
UA110688C2 (uk) * 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
AU2013329348A1 (en) * 2012-10-12 2015-05-28 Teva Pharmaceutical Industries Ltd. Laquinimod for reducing thalamic damage in multiple sclerosis
JP2014101316A (ja) * 2012-11-20 2014-06-05 Toyobo Co Ltd ベンゾ［１，２−ｄ；４，５−ｄ’］ビスチアゾール化合物の製造方法
EP2953949B1 (en) 2012-12-20 2016-09-28 Janssen Pharmaceutica NV Novel tricyclic 3,4-dihydro-2h-pyrido[1,2-a]pyrazine-1,6-dione derivatives as gamma secretase modulators
EP2945944B1 (en) * 2013-01-17 2016-11-09 Janssen Pharmaceutica, N.V. Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
EP3052495B1 (en) * 2013-10-04 2019-06-26 Pfizer Inc Novel bicyclic pyridinones as gamma-secretase modulators
TR201904712T4 (tr) * 2014-01-16 2019-04-22 Fmc Corp Herbisitler olarak pirimidiniloksi benzen türevleri.
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
WO2015150957A1 (en) * 2014-04-01 2015-10-08 Pfizer Inc. Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
CN103965093A (zh) * 2014-04-04 2014-08-06 华南理工大学 2-全氟烷基吲哚类化合物及其制备方法和应用
US20150306088A1 (en) 2014-04-29 2015-10-29 Teva Pharmaceutical Industries, Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
WO2016125048A1 (en) 2015-02-03 2016-08-11 Pfizer Inc. Novel cyclopropabenzofuranyl pyridopyrazinediones
WO2016201168A1 (en) 2015-06-10 2016-12-15 Forum Pharmceuticals Inc. Oxadiazine compounds and methods of use thereof
CA3041243C (en) * 2016-05-31 2021-08-03 Human Biomolecular Research Institute Compounds as inhibitors of sodium channels
WO2018031680A1 (en) * 2016-08-10 2018-02-15 Fronthera U.S. Pharmaceuticals Llc Novel compounds, uses and methods for their preparation
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
CN110256369A (zh) * 2019-07-01 2019-09-20 中国人民大学 一种制备多氟烷基取代的异恶唑化合物的方法

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1419789A (en) 1972-08-02 1975-12-31 Pfizer 2-trifluoromethyl-4-quinolinols
EP0585913B1 (en) 1992-09-04 1997-12-29 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
ATE239797T1 (de) 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
EP0733632B1 (en) 1995-03-24 2003-06-04 Takeda Chemical Industries, Ltd. Cyclic compounds, their production and use as tachykinin receptor antagonists
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
JP3816111B2 (ja) 1997-04-09 2006-08-30 インテレクト・ニューロサイエンシズ・インコーポレーテッド β−アミロイド末端に特異的な組換え抗体、それをコードするＤＮＡ及びその使用法
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
EP1060141B1 (en) 1998-03-03 2002-10-30 PPG Industries Ohio, Inc. Impregnated glass fiber strands and products including the same
US20020132817A1 (en) 1998-03-19 2002-09-19 Hideaki Natsugari Heterocyclic compounds, their production and use
AU1409100A (en) 1998-11-27 2000-06-19 Takeda Chemical Industries Ltd. Drugs
SI1481992T1 (sl) 2000-02-24 2017-01-31 Washington University St. Louis Humanizirana protitelesa, ki vežejo amiloidni peptid beta
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
JP4708675B2 (ja) 2000-11-03 2011-06-22 プロテオテック・インコーポレーテッド ウンカリア・トメントーサおよび関連植物からアミロイド阻害化合物を単離する方法ならびに単離した化合物の使用
WO2003016466A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company ANTI-Aβ ANTIBODIES
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
EP1549315A4 (en) * 2002-09-11 2007-05-23 Merck & Co Inc DIHYDROXYPYRIDOPYRAZINE-1,6-DION COMPOUNDS AS HIV INTEGRASE INHIBITORS
CA2501945A1 (en) 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
WO2004035577A2 (en) 2002-10-16 2004-04-29 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
EP1638935A1 (en) 2003-06-19 2006-03-29 Pfizer Products Inc. Nk1 antagonist
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
US20070155731A1 (en) 2004-01-28 2007-07-05 Gabor Butora Aminocyclopentyl pyridopyrazinone modulators of chemokine receptor activity
BRPI0507374A (pt) 2004-02-02 2007-07-10 Pfizer Prod Inc moduladores do receptor de histamina-3
CN1929737A (zh) 2004-03-09 2007-03-14 默克公司 Hiv整合酶抑制剂
CA2562713A1 (en) 2004-04-14 2005-12-15 Gilead Sciences, Inc. Phosphonate analogs of hiv integrase inhibitor compounds
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
TWI355389B (en) 2004-07-30 2012-01-01 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide a
FR2877015B1 (fr) 2004-10-21 2007-10-26 Commissariat Energie Atomique Revetement nanostructure et procede de revetement.
GB0423356D0 (en) 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
WO2006069081A2 (en) 2004-12-22 2006-06-29 Washington University In St. Louis USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
EP1881825B1 (en) 2005-05-10 2013-07-24 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
PL1881985T3 (pl) 2005-05-12 2011-05-31 Pfizer Bezwodne krystaliczne postacie N-[1-(2-etoksyetylo)-5-(N-etylo-N-metyloamino)-7-(4-metylopirydyn-2-yloamino)-1H-pirazolo[4,3-d]pirymidyno-3-karbonylo]metano-sulfonoamidu
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
WO2006126082A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
CA2603830A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Co Llc PYRIDINE [2,3-B] PYRAZINONES
WO2006136924A1 (en) 2005-06-22 2006-12-28 Pfizer Products Inc. Histamine-3 receptor antagonists
TW200713011A (en) 2005-09-30 2007-04-01 Hon Hai Prec Ind Co Ltd System, method and electrical apparatus for data transferring
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
US20070197532A1 (en) 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
US20070117839A1 (en) 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
AU2006317457B2 (en) 2005-11-24 2011-09-08 Eisai R & D Management Co., Ltd. Morpholine type cinnamide compound
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
PE20071321A1 (es) * 2006-01-20 2007-12-29 Schering Corp Bencensulfonil-cromano, tiocromano, tetrahidronaftaleno e inhibidores de gamma secretasa relacionados
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
EP2007749A2 (en) 2006-03-13 2008-12-31 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
CA2649775C (en) 2006-04-21 2011-05-31 Pfizer Products Inc. Pyridine[3,4-b]pyrazinones
AU2007254190A1 (en) 2006-05-16 2007-11-29 Gilead Sciences, Inc. Integrase inhibitors
EP2019093A4 (en) 2006-05-19 2011-02-23 Eisai R&D Man Co Ltd CINEMA ACID AMID DERIVATIVE FROM THE UREA TYPE
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
WO2008090429A1 (en) 2007-01-22 2008-07-31 Pfizer Products Inc. Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof
JP2010518064A (ja) 2007-02-12 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション Ａｄおよび関連状態の治療のためのピペラジン誘導体
WO2008100412A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperidine derivatives
TW200848054A (en) 2007-02-28 2008-12-16 Eisai R&D Man Co Ltd Two cyclic oxomorpholine derivatives
WO2008137102A2 (en) 2007-05-04 2008-11-13 Torreypines Therapeutics, Inc. Methods of modulating amyloid beta and compounds useful therefor
KR20100017573A (ko) 2007-05-07 2010-02-16 쉐링 코포레이션 감마 세크레타제 조정인자
CA2686754C (en) 2007-05-11 2014-10-28 F. Hoffmann-La Roche Ag Hetarylanilines as modulators for amyloid beta
AU2008263207B2 (en) 2007-06-01 2013-10-03 Merck Sharp & Dohme Corp. Gamma secretase modulators
US8580956B2 (en) 2007-06-01 2013-11-12 Merck Sharp & Dohme Corp. Gamma secretase modulators
WO2008156580A1 (en) 2007-06-13 2008-12-24 Merck & Co., Inc. Triazole derivatives for treating alzheimer's disease and related conditions
WO2009005729A1 (en) 2007-06-29 2009-01-08 Schering Corporation Gamma secretase modulators
EP2185522A1 (en) 2007-08-06 2010-05-19 Schering Corporation Gamma secretase modulators
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
CA2694401C (en) 2007-08-31 2012-12-04 Eisai R&D Management Co., Ltd. Polycyclic compound
EP2200990A1 (en) 2007-09-06 2010-06-30 Schering Corporation Gamma secretase modulators
US20100298381A1 (en) 2007-09-28 2010-11-25 Schering Corporation Gamma secretase modulators
GB0720444D0 (en) 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
US8487099B2 (en) 2007-11-05 2013-07-16 Merck Sharp & Dohme Corp. Gamma secretase modulators
JP2011506336A (ja) * 2007-12-06 2011-03-03 シェーリング コーポレイション γ−セクレターゼ調節剤
WO2009076352A1 (en) 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
MX2010006379A (es) 2007-12-11 2010-09-07 Schering Corp Moduladores de la secretasa gamma.
AU2008335709A1 (en) 2007-12-13 2009-06-18 Amgen Inc. Gamma secretase modulators
BRPI0906799A2 (pt) 2008-01-11 2015-07-14 Hoffmann La Roche Moduladores para amiloide beta
KR101247840B1 (ko) 2008-02-22 2013-03-26 에프. 호프만-라 로슈 아게 아밀로이드 베타 조절제
US20100137320A1 (en) 2008-02-29 2010-06-03 Schering Corporation Gamma secretase modulators
CA2716747A1 (en) 2008-02-29 2009-09-03 Schering Corporation Gamma secretase modulators for the treatment of alzheimer's disease
CA2722606A1 (en) 2008-05-05 2009-11-12 Amgen Inc. Urea compounds as gamma secretase modulators
TW201006801A (en) 2008-07-18 2010-02-16 Lilly Co Eli Imidazole carboxamides
US20110251172A1 (en) 2008-08-13 2011-10-13 Rivkin Alexey A Purine derivatives for treatment of alzheimer's disease
WO2010019393A1 (en) 2008-08-13 2010-02-18 Merck Sharp & Dohme Corp. Pyrimidine derivatives for treatment of alzheimer's disease
CA2733606A1 (en) 2008-08-27 2010-03-04 Eisai R&D Management Co., Ltd. Process for preparing certain cinnamide compounds
MX2011003246A (es) 2008-10-09 2011-04-21 Hoffmann La Roche Moduladores de beta amiloide.
AU2009313524A1 (en) 2008-11-06 2010-05-14 Merck Sharp & Dohme Corp. Gamma secretase modulators
EP2367826A4 (en) 2008-11-06 2012-07-04 Astrazeneca Ab MODULATORS OF THE PROTEIN -AMYLOID
WO2010054078A1 (en) 2008-11-06 2010-05-14 Schering Corporation Gamma secretase modulators
KR101293421B1 (ko) 2008-11-10 2013-08-05 에프. 호프만-라 로슈 아게 헤테로사이클릭 감마 분비효소 조절제
EP2379075A4 (en) 2008-12-16 2012-05-30 Merck Sharp & Dohme TRIAZOL DERIVATIVES FOR THE TREATMENT OF ALZHEIMER DISEASE
WO2010071741A1 (en) 2008-12-16 2010-06-24 Merck Sharp & Dohme Corp. Triazole derivatives for treatment of alzheimer's disease
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
US8759337B2 (en) 2008-12-22 2014-06-24 Merck Sharp & Dohme Corp. Gamma secretase modulators
TW201035103A (en) 2008-12-22 2010-10-01 Schering Corp Gamma secretase modulators
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
BRPI1008473A2 (pt) 2009-02-06 2019-04-02 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. compostos heterocíclicos bicíclicos substituídos como moduladores de gama secretase
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
BRPI1007883A2 (pt) 2009-02-26 2016-02-23 Eisai R&D Man Co Ltd sal, e, cristal.
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
JP2012121809A (ja) 2009-02-26 2012-06-28 Eisai R & D Management Co Ltd 多環式化合物の製造法およびその中間体
JP2012051805A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd テトラヒドロトリアゾロピリジン誘導体の製造方法
CA2751534A1 (en) 2009-03-03 2010-09-10 Pfizer Inc. Novel phenyl imidazoles and phenyl triazoles as gamma-secretase modulators
AU2013261023B2 (en) 2012-05-16 2016-11-24 Cellzome Limited Substituted 3, 4 - dihydro - 2H - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) Alzheimer's disease
US11497586B2 (en) 2014-03-21 2022-11-15 Align Technology, Inc. Segmented orthodontic appliance with elastics

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103787839A (zh) * 2014-01-21 2014-05-14 苏州昊帆生物科技有限公司 合成2, 3, 4, 5, 6-五氟苯酚的方法
CN103787839B (zh) * 2014-01-21 2015-12-02 苏州昊帆生物科技有限公司 合成2,3,4,5,6-五氟苯酚的方法

Also Published As

Publication number Publication date
CA2830027C (en) 2016-04-26
EP2691393A1 (en) 2014-02-05
JP2014510747A (ja) 2014-05-01
JP5767393B2 (ja) 2015-08-19
UY33978A (es) 2012-10-31
US20140045790A1 (en) 2014-02-13
CA2830027A1 (en) 2012-10-04
US9067934B2 (en) 2015-06-30
ES2602794T3 (es) 2017-02-22
WO2012131539A1 (en) 2012-10-04
US20120252758A1 (en) 2012-10-04
EP2691393B1 (en) 2016-09-14
TW201300384A (zh) 2013-01-01
US8697673B2 (en) 2014-04-15

Similar Documents

Publication Publication Date Title
AR085748A1 (es) Piridinonas biciclicas
AR092628A1 (es) Piridinonas biciclicas
AR097571A1 (es) Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa
AR092568A1 (es) Derivados triciclicos de quinolinas y de quinoxalinas
AR102492A1 (es) Cromanos sustituidos y métodos para su uso
PE20160678A1 (es) Inhibidores marcados de antigeno prostatico especifico de membrana (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata
AR085602A1 (es) Inhibidores de quinasas, composiciones farmaceuticas y su aplicacion en el tratamiento de canceres y trastornos autoinmunes
AR062011A1 (es) Derivados de diazol y sus composiciones como inhibidores de itpkb
AR087102A1 (es) Derivados de bencilamina como inhibidores de la calicreina plasmatica
AR093036A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
AR100442A1 (es) Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal
AR092108A1 (es) Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn
AR094550A1 (es) Inhibidores de btk
AR094557A1 (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn
AR085489A1 (es) Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias
AR091279A1 (es) Inhibidores macrociclicos de virus flaviviridae
AR090293A1 (es) Inhibidores de quinasa a base de arileter
AR095530A1 (es) Moduladores de p2x7
AR078549A1 (es) Antagonistas de la via de wnt y composiciones farmaceuticas que los contienen
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR099874A1 (es) CROMENO Y 1,1A,2,7B-TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS COMO MODULADORES DE g-SECRETASA
AR092288A1 (es) Ligandos del receptor ep1
AR092347A1 (es) Derivados de azaindol
PE20161323A1 (es) Compuestos de triazolopiridina, composiciones y metodos de uso de los mismos
AR075249A1 (es) Derivados de 6-(6-o-sustituido-triazolopiridazina-sulfanil) benzotiazoles y bencimidazoles, metodo de preparacion de los mismos e intermediarios de dicha sintesis, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer, artritis, alergias y otras enfermedades.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal